Lieber Institute for Brain Development (LIBD) Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT02652598
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Lieber Institute for Brain Development

Active Ingredients

Drugs in Phase 2 Trials (1)

tolcapone (tasmar) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Brain Injury, Chronic (Phase 2)

Neurocognitive Disorders (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1